


BIOLOGICS, BIOSIMILARS & ONCOLOGY

1.8 million people

in the U.S. were diagnosed with cancer in 2020



BIOLOGICAL MEDICATIONS

offer innovative treatment options.



BIOLOGICS

Made from natural and living sources.

More complex than other drugs.

BIOSIMILARS

Follow-on medicines.

Similar to originator biologics with no clinically meaningful differences.

2015

FDA approved the first biosimilar, which helps patients on chemo.



2017

FDA approved the first biosimilar to treat cancer.



Early evidence suggests

PHYSICIANS ARE COMFORTABLE

prescribing the first FDA-approved anti-cancer biosimilar

According to **2020 SURVEY**



86%

of oncologists would prescribe biosimilars in acceptable indications

23 BIOSIMILARS

for Oncology & Supportive Care

- Immune System Support
- Colorectal Cancer
- Lung Cancer
- Glioblastoma
- Renal Cell Carcinoma
- Cervical Cancer
- Breast Cancer
- Stomach Cancer
- Chemotherapy-Related Anemia
- Non-Hodgkin's Lymphoma



BiologicsPrescribers
COLLABORATIVE
A PROJECT OF AfPA

www.BiologicsPrescribers.org

Sources: American Cancer Society; Cancer.net; The Center for Biosimilars; Spandidos Publications; The Journal of Clinical Oncology